Spyridoula Maraka
Concepts (243)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypothyroidism | 19 | 2024 | 53 | 8.360 |
Why?
| Thyroxine | 22 | 2024 | 47 | 6.940 |
Why?
| Pregnancy Complications | 11 | 2022 | 384 | 4.500 |
Why?
| Thyrotropin | 14 | 2024 | 46 | 2.520 |
Why?
| Thyroid Gland | 8 | 2022 | 93 | 1.740 |
Why?
| Diabetes Mellitus, Type 2 | 8 | 2022 | 486 | 1.720 |
Why?
| Asymptomatic Diseases | 4 | 2021 | 43 | 1.680 |
Why?
| Thyroid Nodule | 9 | 2023 | 40 | 1.530 |
Why?
| Abortion, Spontaneous | 4 | 2021 | 22 | 1.500 |
Why?
| Thyroid Diseases | 4 | 2024 | 36 | 1.460 |
Why?
| Pre-Eclampsia | 2 | 2022 | 56 | 1.360 |
Why?
| Thyroid Neoplasms | 9 | 2023 | 162 | 1.340 |
Why?
| Pregnancy | 15 | 2022 | 2620 | 1.090 |
Why?
| Tachycardia | 2 | 2015 | 32 | 1.070 |
Why?
| Hormone Replacement Therapy | 3 | 2023 | 27 | 1.060 |
Why?
| Bone Density Conservation Agents | 2 | 2015 | 83 | 1.010 |
Why?
| Diphosphonates | 2 | 2015 | 96 | 1.010 |
Why?
| Humans | 75 | 2024 | 54284 | 1.000 |
Why?
| Multiple Endocrine Neoplasia Type 1 | 2 | 2022 | 4 | 1.000 |
Why?
| Osteoporosis | 3 | 2017 | 164 | 0.980 |
Why?
| Cardiovascular Diseases | 3 | 2022 | 476 | 0.940 |
Why?
| Hyperthyroidism | 1 | 2022 | 27 | 0.850 |
Why?
| Neuroendocrine Tumors | 1 | 2022 | 28 | 0.840 |
Why?
| Hypertension, Pregnancy-Induced | 1 | 2022 | 17 | 0.830 |
Why?
| Hypertension | 3 | 2022 | 564 | 0.830 |
Why?
| Female | 39 | 2024 | 28441 | 0.820 |
Why?
| Adult | 29 | 2024 | 14207 | 0.800 |
Why?
| Insulin | 5 | 2022 | 510 | 0.800 |
Why?
| Transsexualism | 2 | 2017 | 7 | 0.790 |
Why?
| Electronic Health Records | 1 | 2023 | 206 | 0.780 |
Why?
| Thyroid Function Tests | 6 | 2024 | 25 | 0.770 |
Why?
| Gonadal Steroid Hormones | 2 | 2017 | 42 | 0.770 |
Why?
| Hypoglycemic Agents | 6 | 2022 | 177 | 0.760 |
Why?
| Iodine | 1 | 2020 | 12 | 0.760 |
Why?
| Suicidal Ideation | 1 | 2021 | 96 | 0.750 |
Why?
| Aircraft | 1 | 2020 | 12 | 0.750 |
Why?
| Diabetes, Gestational | 2 | 2021 | 54 | 0.720 |
Why?
| Infant Mortality | 1 | 2020 | 70 | 0.720 |
Why?
| Health Knowledge, Attitudes, Practice | 3 | 2022 | 543 | 0.710 |
Why?
| Robotics | 1 | 2020 | 45 | 0.710 |
Why?
| Thyroid Hormones | 3 | 2022 | 18 | 0.700 |
Why?
| Malnutrition | 1 | 2020 | 83 | 0.690 |
Why?
| Pancreatic Neoplasms | 1 | 2022 | 234 | 0.680 |
Why?
| Graves Disease | 4 | 2022 | 23 | 0.670 |
Why?
| Triiodothyronine | 4 | 2022 | 29 | 0.660 |
Why?
| Premature Birth | 3 | 2021 | 154 | 0.640 |
Why?
| Rural Health Services | 1 | 2020 | 175 | 0.630 |
Why?
| Pregnancy Outcome | 5 | 2022 | 249 | 0.600 |
Why?
| Endocrinology | 3 | 2022 | 13 | 0.560 |
Why?
| Fetal Growth Retardation | 1 | 2016 | 45 | 0.560 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2020 | 394 | 0.540 |
Why?
| Treatment Outcome | 12 | 2022 | 5604 | 0.530 |
Why?
| Bone Density | 4 | 2017 | 416 | 0.470 |
Why?
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2013 | 4 | 0.470 |
Why?
| Retrospective Studies | 16 | 2024 | 6432 | 0.470 |
Why?
| Teratoma | 1 | 2013 | 24 | 0.460 |
Why?
| Adrenal Gland Neoplasms | 3 | 2017 | 54 | 0.440 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2012 | 40 | 0.430 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2015 | 202 | 0.430 |
Why?
| Middle Aged | 20 | 2024 | 13088 | 0.410 |
Why?
| Blood Glucose | 4 | 2021 | 489 | 0.390 |
Why?
| Antithyroid Agents | 3 | 2022 | 7 | 0.380 |
Why?
| Mammaplasty | 2 | 2021 | 45 | 0.380 |
Why?
| Prescription Drugs | 2 | 2021 | 35 | 0.380 |
Why?
| Male | 23 | 2024 | 27334 | 0.370 |
Why?
| Free Tissue Flaps | 2 | 2021 | 56 | 0.340 |
Why?
| Ovarian Neoplasms | 1 | 2013 | 472 | 0.340 |
Why?
| Iodide Peroxidase | 3 | 2022 | 4 | 0.330 |
Why?
| Myocardial Infarction | 2 | 2022 | 427 | 0.300 |
Why?
| Inappropriate Prescribing | 2 | 2016 | 20 | 0.280 |
Why?
| Hyperparathyroidism, Primary | 2 | 2016 | 50 | 0.280 |
Why?
| Young Adult | 7 | 2024 | 4318 | 0.280 |
Why?
| Parathyroidectomy | 2 | 2016 | 75 | 0.270 |
Why?
| Decision Making | 3 | 2021 | 290 | 0.270 |
Why?
| Risk Assessment | 3 | 2021 | 1361 | 0.260 |
Why?
| United States | 7 | 2024 | 5217 | 0.250 |
Why?
| Biopsy, Fine-Needle | 4 | 2018 | 116 | 0.230 |
Why?
| Risk Factors | 4 | 2021 | 3935 | 0.220 |
Why?
| Adolescent | 6 | 2024 | 6897 | 0.220 |
Why?
| Peripheral Vascular Diseases | 1 | 2022 | 24 | 0.220 |
Why?
| Vasoactive Intestinal Peptide | 1 | 2022 | 18 | 0.210 |
Why?
| Cross-Sectional Studies | 3 | 2022 | 1693 | 0.200 |
Why?
| Thyroidectomy | 2 | 2020 | 103 | 0.200 |
Why?
| Chorionic Gonadotropin | 1 | 2021 | 15 | 0.200 |
Why?
| Aged | 13 | 2022 | 10054 | 0.200 |
Why?
| Abdominoplasty | 1 | 2021 | 3 | 0.200 |
Why?
| Abdominal Wall | 1 | 2021 | 10 | 0.200 |
Why?
| Metformin | 1 | 2022 | 66 | 0.200 |
Why?
| Negative-Pressure Wound Therapy | 1 | 2020 | 10 | 0.190 |
Why?
| Ultrasonography, Interventional | 3 | 2016 | 146 | 0.190 |
Why?
| Transforming Growth Factor beta | 1 | 2021 | 158 | 0.190 |
Why?
| Thyroid (USP) | 1 | 2020 | 1 | 0.190 |
Why?
| Islands | 1 | 2020 | 2 | 0.190 |
Why?
| Electronic Prescribing | 1 | 2020 | 4 | 0.190 |
Why?
| Ireland | 1 | 2020 | 11 | 0.190 |
Why?
| Pheochromocytoma | 2 | 2017 | 38 | 0.190 |
Why?
| Diabetes Mellitus | 2 | 2022 | 309 | 0.180 |
Why?
| Iodine Radioisotopes | 1 | 2020 | 43 | 0.180 |
Why?
| Patient Safety | 1 | 2021 | 121 | 0.180 |
Why?
| Specimen Handling | 1 | 2020 | 62 | 0.180 |
Why?
| Patients | 1 | 2020 | 53 | 0.180 |
Why?
| Patient Participation | 2 | 2021 | 70 | 0.180 |
Why?
| Hypoglycemia | 1 | 2019 | 61 | 0.170 |
Why?
| Perception | 1 | 2020 | 143 | 0.170 |
Why?
| Prospective Studies | 2 | 2022 | 2604 | 0.160 |
Why?
| Multiple Endocrine Neoplasia Type 2a | 1 | 2017 | 6 | 0.160 |
Why?
| Patient Education as Topic | 1 | 2021 | 313 | 0.160 |
Why?
| Databases, Factual | 2 | 2020 | 684 | 0.160 |
Why?
| Lower Extremity | 1 | 2018 | 103 | 0.150 |
Why?
| Ischemia | 1 | 2018 | 177 | 0.150 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2017 | 35 | 0.150 |
Why?
| Stroke | 1 | 2022 | 526 | 0.140 |
Why?
| Follow-Up Studies | 3 | 2017 | 2387 | 0.140 |
Why?
| Telemedicine | 1 | 2022 | 449 | 0.140 |
Why?
| Apgar Score | 1 | 2016 | 35 | 0.140 |
Why?
| Bronchial Neoplasms | 1 | 2015 | 5 | 0.140 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2017 | 205 | 0.140 |
Why?
| Time Factors | 2 | 2021 | 3213 | 0.140 |
Why?
| Physical Examination | 1 | 2016 | 99 | 0.140 |
Why?
| Carcinoid Tumor | 1 | 2015 | 21 | 0.140 |
Why?
| Thymus Neoplasms | 1 | 2015 | 17 | 0.140 |
Why?
| Infant, Low Birth Weight | 1 | 2016 | 75 | 0.140 |
Why?
| Pancreas, Artificial | 1 | 2015 | 1 | 0.130 |
Why?
| Infant | 2 | 2024 | 3817 | 0.130 |
Why?
| Sensitivity and Specificity | 4 | 2021 | 923 | 0.130 |
Why?
| Adipocytes | 1 | 2016 | 129 | 0.130 |
Why?
| Ultrasonography | 3 | 2022 | 480 | 0.130 |
Why?
| Mutation | 1 | 2022 | 1501 | 0.130 |
Why?
| Computer Security | 1 | 2015 | 22 | 0.130 |
Why?
| Multivariate Analysis | 1 | 2017 | 643 | 0.130 |
Why?
| Intensive Care Units, Neonatal | 1 | 2016 | 117 | 0.130 |
Why?
| Stress, Physiological | 1 | 2016 | 194 | 0.130 |
Why?
| Postoperative Complications | 2 | 2020 | 1033 | 0.130 |
Why?
| Anthropometry | 1 | 2015 | 96 | 0.130 |
Why?
| Cell Transformation, Neoplastic | 1 | 2016 | 200 | 0.130 |
Why?
| Arkansas | 1 | 2021 | 2100 | 0.130 |
Why?
| Tomography, X-Ray Computed | 2 | 2017 | 1213 | 0.120 |
Why?
| Fractures, Bone | 1 | 2015 | 119 | 0.120 |
Why?
| Bariatric Surgery | 1 | 2015 | 43 | 0.120 |
Why?
| Postoperative Period | 1 | 2015 | 189 | 0.120 |
Why?
| Early Detection of Cancer | 1 | 2015 | 162 | 0.120 |
Why?
| Logistic Models | 1 | 2017 | 995 | 0.120 |
Why?
| Biopsy | 1 | 2016 | 692 | 0.120 |
Why?
| White Coat Hypertension | 1 | 2012 | 1 | 0.110 |
Why?
| Quality of Life | 4 | 2022 | 922 | 0.110 |
Why?
| Time | 1 | 2012 | 36 | 0.110 |
Why?
| Case-Control Studies | 1 | 2016 | 1228 | 0.110 |
Why?
| Body Weight | 1 | 2015 | 578 | 0.110 |
Why?
| Circadian Rhythm | 1 | 2012 | 85 | 0.110 |
Why?
| Practice Guidelines as Topic | 1 | 2015 | 492 | 0.100 |
Why?
| Risk | 1 | 2012 | 343 | 0.100 |
Why?
| Aged, 80 and over | 4 | 2022 | 3431 | 0.100 |
Why?
| Renal Insufficiency | 1 | 2012 | 138 | 0.100 |
Why?
| Antihypertensive Agents | 1 | 2012 | 139 | 0.100 |
Why?
| Bone and Bones | 1 | 2015 | 516 | 0.100 |
Why?
| Glucose | 2 | 2022 | 366 | 0.090 |
Why?
| Drug Utilization | 2 | 2021 | 74 | 0.080 |
Why?
| Image-Guided Biopsy | 2 | 2016 | 35 | 0.070 |
Why?
| Infant, Newborn | 2 | 2022 | 2907 | 0.060 |
Why?
| Cohort Studies | 2 | 2021 | 1543 | 0.060 |
Why?
| Predictive Value of Tests | 2 | 2017 | 1048 | 0.060 |
Why?
| Policy | 1 | 2022 | 27 | 0.060 |
Why?
| Thyroglobulin | 1 | 2022 | 11 | 0.050 |
Why?
| Goals | 1 | 2022 | 50 | 0.050 |
Why?
| Immunization, Passive | 1 | 2022 | 35 | 0.050 |
Why?
| Odds Ratio | 1 | 2024 | 604 | 0.050 |
Why?
| Reference Values | 1 | 2022 | 354 | 0.050 |
Why?
| Androgens | 1 | 2022 | 68 | 0.050 |
Why?
| Insurance Claim Review | 1 | 2021 | 28 | 0.050 |
Why?
| Counseling | 1 | 2023 | 149 | 0.050 |
Why?
| Autoantibodies | 1 | 2022 | 132 | 0.050 |
Why?
| Colombia | 1 | 2021 | 13 | 0.050 |
Why?
| Iron-Binding Proteins | 1 | 2021 | 2 | 0.050 |
Why?
| Physician-Patient Relations | 1 | 2023 | 150 | 0.050 |
Why?
| Autoimmunity | 1 | 2021 | 38 | 0.050 |
Why?
| Parity | 1 | 2021 | 51 | 0.050 |
Why?
| Maternal Age | 1 | 2021 | 46 | 0.050 |
Why?
| Evidence-Based Medicine | 1 | 2022 | 281 | 0.050 |
Why?
| Glucose Tolerance Test | 1 | 2021 | 67 | 0.050 |
Why?
| Decision Support Techniques | 1 | 2021 | 74 | 0.050 |
Why?
| China | 1 | 2021 | 104 | 0.050 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2021 | 55 | 0.050 |
Why?
| Ambulatory Care | 1 | 2022 | 230 | 0.050 |
Why?
| Medication Adherence | 1 | 2022 | 135 | 0.050 |
Why?
| Autoantigens | 1 | 2021 | 64 | 0.050 |
Why?
| Communication | 1 | 2023 | 273 | 0.050 |
Why?
| Florida | 1 | 2020 | 59 | 0.050 |
Why?
| Abdomen | 1 | 2020 | 83 | 0.050 |
Why?
| Linear Models | 1 | 2021 | 309 | 0.050 |
Why?
| Drug Therapy, Combination | 1 | 2021 | 426 | 0.050 |
Why?
| Documentation | 1 | 2019 | 32 | 0.050 |
Why?
| Medicare | 1 | 2021 | 241 | 0.050 |
Why?
| Educational Status | 1 | 2021 | 260 | 0.040 |
Why?
| Blood Pressure | 1 | 2022 | 587 | 0.040 |
Why?
| Immunosuppressive Agents | 1 | 2021 | 248 | 0.040 |
Why?
| Oxygen | 1 | 2022 | 361 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2021 | 596 | 0.040 |
Why?
| Optical Imaging | 1 | 2018 | 30 | 0.040 |
Why?
| Disease Management | 1 | 2020 | 184 | 0.040 |
Why?
| Tibial Fractures | 1 | 2018 | 34 | 0.040 |
Why?
| Femur Neck | 1 | 2017 | 8 | 0.040 |
Why?
| Social Media | 1 | 2020 | 105 | 0.040 |
Why?
| Body Mass Index | 1 | 2021 | 713 | 0.040 |
Why?
| Hospitalization | 1 | 2022 | 705 | 0.040 |
Why?
| Incidence | 1 | 2020 | 1082 | 0.040 |
Why?
| Osteomyelitis | 1 | 2018 | 122 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 217 | 0.040 |
Why?
| Recurrent Laryngeal Nerve Injuries | 1 | 2016 | 11 | 0.040 |
Why?
| Methimazole | 1 | 2016 | 2 | 0.040 |
Why?
| Hypocalcemia | 1 | 2016 | 13 | 0.040 |
Why?
| 3T3-L1 Cells | 1 | 2016 | 16 | 0.040 |
Why?
| Lumbar Vertebrae | 1 | 2017 | 105 | 0.040 |
Why?
| Hypercalcemia | 1 | 2016 | 36 | 0.040 |
Why?
| Caloric Restriction | 1 | 2016 | 37 | 0.040 |
Why?
| Health Literacy | 1 | 2018 | 141 | 0.030 |
Why?
| Primary Health Care | 1 | 2019 | 401 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2016 | 107 | 0.030 |
Why?
| Health Care Surveys | 1 | 2016 | 195 | 0.030 |
Why?
| Observer Variation | 1 | 2016 | 138 | 0.030 |
Why?
| Endpoint Determination | 1 | 2015 | 30 | 0.030 |
Why?
| Uncertainty | 1 | 2015 | 46 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2016 | 252 | 0.030 |
Why?
| Madagascar | 1 | 2015 | 2 | 0.030 |
Why?
| Diagnostic Errors | 1 | 2016 | 74 | 0.030 |
Why?
| Lipids | 1 | 2016 | 178 | 0.030 |
Why?
| Metabolomics | 1 | 2016 | 149 | 0.030 |
Why?
| Child, Preschool | 1 | 2024 | 4147 | 0.030 |
Why?
| Patient-Centered Care | 1 | 2016 | 134 | 0.030 |
Why?
| Diagnosis, Differential | 1 | 2018 | 1136 | 0.030 |
Why?
| Insulin Resistance | 1 | 2016 | 300 | 0.030 |
Why?
| Proteomics | 1 | 2016 | 343 | 0.030 |
Why?
| Referral and Consultation | 1 | 2015 | 307 | 0.030 |
Why?
| Proteins | 1 | 2016 | 376 | 0.030 |
Why?
| Pilot Projects | 1 | 2015 | 808 | 0.030 |
Why?
| Registries | 1 | 2015 | 553 | 0.030 |
Why?
| Cells, Cultured | 1 | 2016 | 1737 | 0.030 |
Why?
| MicroRNAs | 1 | 2016 | 386 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2016 | 1999 | 0.020 |
Why?
| Prognosis | 1 | 2016 | 2118 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2015 | 1604 | 0.020 |
Why?
| Obesity | 1 | 2016 | 1202 | 0.020 |
Why?
| Mice | 1 | 2016 | 6413 | 0.020 |
Why?
| Animals | 1 | 2016 | 14385 | 0.010 |
Why?
|
|
Maraka's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|